CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE TOURS;INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE);UNIVERSITÉ DE TOURS FRANÇOIS RABELAIS
发明人:
Laurent PLANTIER
申请号：
US16754826
公开号：
US20200237864A1
申请日:
2018.10.09
申请国别(地区):
US
年份:
2020
代理人:
摘要：
In the present invention, inventors study in fibrotic ILD/IPF mechanism, the role of Arp2/3 multiprotein complex which regulates the branched polymerization of the actin cytoskeleton, and may play key roles in mechanotranduction. Inventors demonstrated that the expression of the Arp2/3 complex is increased in IPF lung mesenchymal cells and in mouse lungs during fibrogenesis, and that the inhibition of Arp2/3 complex with the small molecule CK666 blocks collagen expression in the lungs and prevents the development of bleomycin-induced lung fibrosis in mice. Accordingly the present invention relates to an inhibitor of Arp2/3 complex activity or expression for use in a method for treating Fibrotic interstitial lung diseases (ILD) such as idiopathic pulmonary fibrosis in a subject in need thereof.
